Sera Prognostics is focused on revolutionizing pregnancy care to address the challenge of preterm birth.
Their flagship product, PreTRM®, is a clinically validated test for early prediction of premature birth risk.
The company is positioning itself as a leader in high-value women's health diagnostics, aiming to improve maternal and neonatal outcomes.
Bold Ambition
To become a global leader in high-value women's health diagnostics by providing pivotal information to improve healthcare outcomes for moms and babies.
Financial Strength
Sera Prognostics has $108.5 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which can support their commercialization efforts through 2028.
Commercial Strategy
The company is actively engaging Medicaid plans in targeted states with prior PreTRM clinical study experience, aiming to address the economic cost of preterm birth in the US.
Clinical Validation
PreTRM® is verified by 8 independent clinical studies and is the only clinically validated test available for early prediction of spontaneous preterm birth.
- Sera Prognostics aims to usher in a new era of personalized pregnancy care through predictive diagnostics, leveraging proteomics-based testing for women's health.
- With rising preterm birth rates and increasing NICU admissions, there is a pressing need for innovative solutions like PreTRM® to improve maternal and neonatal outcomes.
Sera Prognostics is at the forefront of addressing the challenges of preterm birth with their innovative diagnostic solutions. With a strong financial position and a focus on clinical validation, the company is poised to make a significant impact in improving pregnancy care outcomes.